Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:

NCT ID: NCT04524273 Active, not recruiting - Myasthenia Gravis Clinical Trials

Myasthenia Gravis Inebilizumab Trial

MINT
Start date: August 30, 2020
Phase: Phase 3
Study type: Interventional

Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.

NCT ID: NCT04431895 Recruiting - Clinical trials for Myasthenia Gravis, Generalized

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

Start date: June 11, 2020
Phase: Early Phase 1
Study type: Interventional

This is a 6 month study that will evaluate the efficacy of 5mg tofacitinib tablet taken twice a day in patients with refractory myasthenia gravis. Twenty adult participants will receive a four month treatment of tofacitinib followed by elution for one month.

NCT ID: NCT04346888 Completed - Myasthenia Gravis Clinical Trials

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Start date: July 23, 2020
Phase: Phase 2
Study type: Interventional

Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China

NCT ID: NCT04302103 Completed - Clinical trials for Systemic Myasthenia Gravis

A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Start date: July 7, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.

NCT ID: NCT04226170 Recruiting - Myasthenia Gravis Clinical Trials

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Start date: April 8, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

NCT ID: NCT04225871 Active, not recruiting - Clinical trials for Generalized Myasthenia Gravis

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

RAISE-XT
Start date: December 23, 2019
Phase: Phase 3
Study type: Interventional

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

NCT ID: NCT04224506 Recruiting - Myasthenia Gravis Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04202341 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Start date: December 2, 2019
Phase:
Study type: Observational [Patient Registry]

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

NCT ID: NCT04182984 Recruiting - Clinical trials for Ocular Myasthenia Gravis

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

TREAT-OMG
Start date: November 4, 2019
Phase:
Study type: Observational [Patient Registry]

This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).

NCT ID: NCT04176211 Completed - Myasthenia Gravis Clinical Trials

The Impact of Myasthenia Gravis in the Real World

Start date: December 12, 2019
Phase:
Study type: Observational [Patient Registry]

An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's natural history, its burden on patients and their families, its treatment, as well as its medical, social and pharmacoeconomic impact.